logo
explain how to read the page

The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 4
  • 1
    Bond, John Matthew
    Born in March 1961
    Individual (1 offspring)
    Officer
    2023-08-18 ~ now
    OF - Director → CIF 0
  • 2
    Mr Steven Bruce Klinsky
    Born in May 1956
    Individual (17 offsprings)
    Person with significant control
    2022-07-07 ~ now
    PE - Ownership of voting rights - 75% or more → CIF 0
  • 3
    Ronco, Peter
    Born in May 1972
    Individual (1 offspring)
    Officer
    2023-09-20 ~ now
    OF - Director → CIF 0
  • 4
    Chilukuri, Sastry Venkata
    Born in February 1975
    Individual (1 offspring)
    Officer
    2023-09-20 ~ now
    OF - Director → CIF 0
Ceased 14
  • 1
    Decarlo, Jonathan Paul
    Chief Financial Officer born in January 1980
    Individual
    Officer
    2022-12-21 ~ 2023-06-30
    OF - Director → CIF 0
  • 2
    Mangroo, Rajmattie Kumarie
    Individual (1 offspring)
    Officer
    2008-04-01 ~ 2012-02-29
    OF - Secretary → CIF 0
  • 3
    Ollier, Susan
    Clincial Research born in August 1955
    Individual (2 offsprings)
    Officer
    2009-09-15 ~ 2014-02-19
    OF - Director → CIF 0
  • 4
    Ogorka, Thomas
    Pharmaceutical born in June 1964
    Individual (3 offsprings)
    Officer
    2002-07-30 ~ 2022-12-22
    OF - Director → CIF 0
    Mr Thomas Ogorka
    Born in June 1964
    Individual (3 offsprings)
    Person with significant control
    2016-04-06 ~ 2021-05-11
    PE - Ownership of shares – 75% or more → CIF 0
  • 5
    Henry, Rhonda Usilton
    President, Emmes Biopharma born in May 1967
    Individual
    Officer
    2022-12-21 ~ 2023-08-15
    OF - Director → CIF 0
  • 6
    Marek, Pavel
    Managing Director born in March 1962
    Individual (1 offspring)
    Officer
    2022-12-21 ~ 2023-08-17
    OF - Director → CIF 0
  • 7
    Glickfield Bang, Debra
    Chief Legal Officer born in January 1963
    Individual
    Officer
    2022-03-07 ~ 2023-07-07
    OF - Director → CIF 0
    Bang, Debra Glickfield
    Individual
    Officer
    2022-12-22 ~ 2023-07-07
    OF - Secretary → CIF 0
  • 8
    Vadodaria, Sheetal
    Individual (1 offspring)
    Officer
    2014-09-24 ~ 2022-12-22
    OF - Secretary → CIF 0
  • 9
    Van Veldhuisen, Paul
    President, Emmes Public Sector born in November 1969
    Individual
    Officer
    2022-12-21 ~ 2023-08-15
    OF - Director → CIF 0
  • 10
    Ogorka, Nazira Khalid
    Director Clinical Operations & Global Partnering born in February 1968
    Individual (3 offsprings)
    Officer
    2012-11-01 ~ 2022-09-02
    OF - Director → CIF 0
    Ogorka, Nazira Khalid
    Individual (3 offsprings)
    Officer
    2002-07-30 ~ 2008-03-31
    OF - Secretary → CIF 0
    Mrs Nazira Ogorka
    Born in February 1968
    Individual (3 offsprings)
    Person with significant control
    2016-04-06 ~ 2021-05-11
    PE - Has significant influence or control → CIF 0
  • 11
    Dingivan, Christine
    President And Ceo Of Emmes born in March 1967
    Individual
    Officer
    2022-12-21 ~ 2023-09-20
    OF - Director → CIF 0
  • 12
    Budd, Wendy
    Individual
    Officer
    2012-03-01 ~ 2014-09-24
    OF - Secretary → CIF 0
  • 13
    Mellier House, 26a Albemarle Street, London
    Active Corporate (1 parent, 212 offsprings)
    Equity (Company account)
    1 GBP2024-12-31
    Officer
    2002-07-30 ~ 2002-07-30
    PE - Nominee Secretary → CIF 0
  • 14
    C/o Ct Corporation System, 4701 Cox Road, Suite 285, Glen Allen, Postal Code 23060, Virginia, United States
    Corporate
    Person with significant control
    2021-05-11 ~ 2022-07-07
    PE - Ownership of shares – 75% or more → CIF 0
parent relation
Company in focus

EMMES BIOPHARMA UK LIMITED

Previous names
ORPHAN REACH LIMITED - 2023-01-05
QED CLINICAL SERVICES LIMITED - 2018-07-20
MONITORDIRECT LIMITED - 2002-10-01
Standard Industrial Classification
72190 - Other Research And Experimental Development On Natural Sciences And Engineering
Brief company account
Par Value of Share
Class 1 ordinary share
02024-01-01 ~ 2024-12-31
Class 2 ordinary share
02024-01-01 ~ 2024-12-31
Class 3 ordinary share
02024-01-01 ~ 2024-12-31
Intangible Assets
195,329 GBP2024-12-31
239,327 GBP2023-12-31
Property, Plant & Equipment
4,276 GBP2024-12-31
5,195 GBP2023-12-31
Fixed Assets - Investments
405,222 GBP2024-12-31
421,756 GBP2023-12-31
Fixed Assets
604,827 GBP2024-12-31
666,278 GBP2023-12-31
Debtors
15,495,129 GBP2024-12-31
14,334,473 GBP2023-12-31
Cash at bank and in hand
1,152,919 GBP2024-12-31
1,588,173 GBP2023-12-31
Current Assets
16,648,048 GBP2024-12-31
15,922,646 GBP2023-12-31
Creditors
Current
4,393,948 GBP2024-12-31
4,990,202 GBP2023-12-31
Net Current Assets/Liabilities
12,254,100 GBP2024-12-31
10,932,444 GBP2023-12-31
Total Assets Less Current Liabilities
12,858,927 GBP2024-12-31
11,598,722 GBP2023-12-31
Net Assets/Liabilities
12,784,684 GBP2024-12-31
11,524,479 GBP2023-12-31
Equity
Called up share capital
1,954 GBP2024-12-31
1,954 GBP2023-12-31
Share premium
97,805 GBP2024-12-31
97,805 GBP2023-12-31
Retained earnings (accumulated losses)
12,684,925 GBP2024-12-31
11,424,720 GBP2023-12-31
Equity
12,784,684 GBP2024-12-31
11,524,479 GBP2023-12-31
Average Number of Employees
312024-01-01 ~ 2024-12-31
452023-01-01 ~ 2023-12-31
Intangible Assets - Gross Cost
Computer software
307,678 GBP2023-12-31
Property, Plant & Equipment - Gross Cost
Plant and equipment
13,922 GBP2024-12-31
10,962 GBP2023-12-31
Furniture and fittings
122 GBP2024-12-31
122 GBP2023-12-31
Property, Plant & Equipment - Gross Cost
14,044 GBP2024-12-31
11,084 GBP2023-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Plant and equipment
9,646 GBP2024-12-31
5,767 GBP2023-12-31
Furniture and fittings
122 GBP2024-12-31
122 GBP2023-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
9,768 GBP2024-12-31
5,889 GBP2023-12-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Plant and equipment
3,879 GBP2024-01-01 ~ 2024-12-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
3,879 GBP2024-01-01 ~ 2024-12-31
Property, Plant & Equipment
Plant and equipment
4,276 GBP2024-12-31
5,195 GBP2023-12-31
Trade Debtors/Trade Receivables
Current
2,257,910 GBP2024-12-31
4,672,696 GBP2023-12-31
Other Debtors
Current
115,665 GBP2024-12-31
Amount of corporation tax that is recoverable
Current
1,895,895 GBP2024-12-31
1,497,203 GBP2023-12-31
Prepayments/Accrued Income
Current
296,098 GBP2024-12-31
769,461 GBP2023-12-31
Prepayments
Current
9,319 GBP2024-12-31
70,276 GBP2023-12-31
Debtors
Amounts falling due within one year, Current
15,495,129 GBP2024-12-31
14,334,473 GBP2023-12-31
Trade Creditors/Trade Payables
Current
2,336,902 GBP2024-12-31
2,130,102 GBP2023-12-31
Other Taxation & Social Security Payable
Current
65,682 GBP2024-12-31
776,977 GBP2023-12-31
Accrued Liabilities/Deferred Income
Current
1,261,774 GBP2024-12-31
1,356,779 GBP2023-12-31
Accrued Liabilities
Current
712,164 GBP2024-12-31
711,059 GBP2023-12-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
Amounts falling due within one year
561 GBP2024-12-31
8,404 GBP2023-12-31
Between one and five year
176 GBP2024-12-31
737 GBP2023-12-31
All periods
737 GBP2024-12-31
9,141 GBP2023-12-31
Amounts set aside to cover potential liabilities or losses
Deferred taxation
74,243 GBP2024-12-31
74,243 GBP2023-12-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
12,390 shares2024-12-31
Class 2 ordinary share
350 shares2024-12-31
Class 3 ordinary share
680 shares2024-12-31
  • EMMES BIOPHARMA UK LIMITED
    Info
    ORPHAN REACH LIMITED - 2023-01-05
    QED CLINICAL SERVICES LIMITED - 2023-01-05
    MONITORDIRECT LIMITED - 2023-01-05
    Registered number 04498663
    Regus House Fairbourne Drive, Atterbury, Milton Keynes MK10 9RG
    PRIVATE LIMITED COMPANY incorporated on 2002-07-30 (23 years 6 months). The company status is Active.
    The last date of confirmation statement was made at 2024-11-17
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

qrcode

Privacy notice

Terms and conditions

The content of this website is protected by AgonGuard.

© 2022- Polylogarithmic Technology Ltd (Registered in England and Wales No. 14256313). All rights reserved.

Contains public sector information retrieved at 9 February 2026 and licensed under the Open Government Licence v3.0.